Vasoactive intestinal peptide modulates langerhans cell immune function

Journal of Immunology

Volumn 173, Issue 10, 2004, Pages 6082-6088

  Kodali, Sreedevi ^a   Ding, Wanhong ^a   Huang, Jing ^a   Seiffert, Kristina ^a   Wagner, John A ^a   Granstein, Richard D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRIDOMA; IMMUNIZATION; IMMUNOMODULATION; LANGERHANS CELL; LYMPHOCYTE CLONE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN NERVE;

EID: 8444236264     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.10.6082     Document Type: Article

References (58)

1. Hosoi, J., G. F. Murphy, C. L. Egan, E. A. Lerner, S. Grabbe, A. Asahina, and R. D. Granstein. 1993. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 363:159.
2. Toni, H., J. Hosoi, S. Beissert, S. Xu, F. E. Fox, A. Asahina, A. Takashima, A. H. Rook, and R. D. Granstein. 1997. Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide. J. Leukocyte Biol. 61:216.
3. Asahina, A., J. Hosoi, S. Beissert, A. Stratigos, and R. D. Granstein. 1995. Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J. Immunol. 154:3056.
4. Bhardwaj, R. S., A. Schwarz, E. Becher, K. Mahnke, Y. Aragane, T. Schwarz, and T. A. Luger. 1996. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. J. Immunol. 156:2517.
5. Grabbe, S., R. S. Bhardwaj, K. Mahnke, M. M. Simon, T. Schwarz, and T. A. Luger. 1996. α-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J. Immunol. 156:473.
6. Kodali, S., I. Friedman, W. Ding, K. Seiffert, J. A. Wagner, and R. D. Granstein. 2003. Pituitary adenylate cyclase-activating polypeptide inhibits cutaneous immune function. Eur. J. Immunol. 33:3070.
7. Laburthe, M., A. Couvineau, and J. C. Marie. 2002. VPAC receptors for VIP and PACAP. Recept. Channels 8:137.
8. Sherwood, N. M., S. L. Krueckl, and J. E. McRory. 2000. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21:619.
9. Said, S. I., and V. Mutt. 1970. Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217.
10. Gozes, I., and D. E. Brenneman. 1989. VIP: molecular biology and neurobiological function. Mol. Neurobiol. 3:201.
11. Delgado, M., E. J. Munoz-Elias, C. Martinez, R. P. Gomariz, and D. Ganea. 1999. VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann. NY Acad. Sci. 897:401.
12. Delgado, M., W. Sun, J. Leceta, and D. Ganea. 1999. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J. Immunol. 163:4213.
13. Delgado, M., C. Martinez, D. Pozo, J. R. Calvo, J. Leceta, D. Ganea, and R. P. Gomariz. 1999. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162:1200.
14. Delgado, M. 2003. VIP: a very important peptide in T helper differentiation. Trends Immunol. 24:221.
15. Delgado, M., and D. Ganea. 2001. VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors. Arch. Physiol. Biochem. 109:372.
16. Schulze, E., M. Witt, T. Fink, A. Hofer, and R. H. Funk. 1997. Immunohistochemical detection of human skin nerve fibers. Acta Histochem. 99:301.
17. Wallengren, J., R. Ekman, and F. Sundler. 1987. Occurrence and distribution of neuropeptides in the human skin: an immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Derm. Venereol. 67:185.
18. Torii, H., Z. Van, J. Hosoi, and R. D. Granstein. 1997. Expression of neurotrophic factors and neuropeptide receptors by Langerhans cells and the Langerhans cell-like cell line XS52: further support for a functional relationship between Langerhans cells and epidermal nerves. J. Invest. Dermatol. 109:586.
19. Mittag, T. W., A. Tormay, and S. M. Podos. 1987. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes. J. Pharmacol. Exp. Ther. 241:230.
20. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162:1707.
21. Xu, S., K. Ariizumi, G. Caceres-Dittmar, D. Edelbaum, K. Hashimoto, P. R. Bergstresser, and A. Takashima. 1995. Successive generation of antigen-presenting, dendritic cell lines from murine epidermis. J. Immunol. 154:2697.
22. Xu, S., K. Ariizumi, D. Edelbaum, P. R. Bergstresser, and A. Takashima. 1995. Cytokine-dependent regulation of growth and maturation in murine epidermal dendritic cell lines. Eur. J. Immunol. 25:1018.
23. Schuhmachers, G., S. Xu, P. R. Bergstresser, and A. Takashima. 1995. Identity and functional properties of novel skin-derived fibroblast lines (NS series) that support the growth of epidermal-derived dendritic cell lines. J. Invest. Dermatol. 105:225.
24. + cells of the T helper 2 subset. J. Immunol. 145:2087.
25. Greene, M. I., and L. L. Perry. 1978. Regulation of the immune response to tumor antigen. VI. Differential specificities of suppressor T cells or their products and effector T cells. J. Immunol. 121:2363.
26. Shimonkevitz, R., S. Colon, J. W. Kappler, P. Marrack, and H. M. Grey. 1984. Antigen recognition by H-2-restricted T cells. H. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133:2067.
27. Granstein, R. D., M. Askari, D. Whitaker, and G. F. Murphy. 1987. Epidermal cells in activation of suppressor lymphocytes: further characterization. J. Immunol. 138:4055.
28. Schuler, G., and R. M. Steinman. 1985. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J. Exp. Med. 161:526.
29. Ferrick, D. A., M. D. Schrenzel, T. Mulvania, B. Hsieh, W. G. Ferlin, and H. Lepper. 1995. Differential production of interferon-γ and interleukin-4 in response to Th1- and Th2-stimulating pathogens by γδ T cells in vivo. Nature 373:255.
30. Pozo, D., J. M. Guerrero, and J. R. Calvo. 2002. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1α production and mRNA expression. Cytokine 18:35.
31. Pratt, J. C., M. R. van den Brink, V. E. Igras, S. F. Walk, K. S. Ravichandran, and S. J. Burakoff. 1999. Requirement for She in TCR-mediated activation of a T cell hybridoma. J. Immunol. 163:2586.
32. + T cells. J. Leukocyte Biol. 75:1122.
33. Heufler, C., F. Koch, and G. Schuler. 1988. Granulocyte/Macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167:700.
34. Wang, B., P. Amerio, and D. N. Sauder. 1999. Role of cytokines in epidermal Langerhans cell migration. J. Leukocyte Biol. 66:33.
35. Enk, A. H., V. L. Angeloni, M. C. Udey, and S. I. Katz. 1993. An essential role for Langerhans cell-derived IL-1β in the initiation of primary immune responses in skin. J. Immunol 150:3698.
36. Ozawa, H., S. Aiba, S. Nakagawa, and H. Tagami. 1996. Interferon-γ and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression. Eur. J. Immunol. 26:648.
37. Suemoto, Y., O. Ando, M. Kurimoto, T. Horikawa, and M. Ichihashi. 1998. IL-12 promotes the accessory cell function of epidermal Langerhans cells. J. Dermatol. Sci. 18:98.
38. Matsue, H., P. D. Cruz, Jr., P. R. Bergstresser, and A. Takashima. 1992. Langerhans cells are the major source of mRNA for IL-10 and MIP-1α among unstimulated mouse epidermal cells. J. Invest. Dermatol. 99:537.
39. Cumberbatch, M., R. J. Dearman, and I. Kimber. 1997. Stimulation of Langerhans cell migration in mice by tumor necrosis factor α and interleukin 1β. Adv. Exp. Med. Biol. 417:121.
40. Ozawa, H., S. Nakagawa, H. Tagami, and S. Aiba. 1996. Interleukin-1β and granulocyte-macrophage colony-stimulating factor mediate Langerhans cell maturation differently. J. Invest. Dermatol. 106:441.
41. Panzer, S., M. Madden, and K. Matsuki. 1993. Interaction of IL-1β, IL-6 and tumor necrosis factor-α (TNF-α) in human T cells activated by murine antigens. Clin. Exp. Immunol. 93:471.
42. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. 1999. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages: subsequent effect on IFNγ synthesis by T cells. J. Neuroimmunol. 96:167.
43. Kang, K., M. Kubin, K. D. Cooper, S. R. Lessin, G. Trinchieri, and A. H. Rook. 1996. IL-12 synthesis by human Langerhans cells. J. Immunol. 156:1402.
44. Berberich, C., J. R. Ramirez-Pineda, C. Hambrecht, G. Alber, Y. A. Skeiky, and H. Moll. 2003. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J. Immunol. 170:3171.
45. Wang, B., L. Zhuang, H. Fujisawa, G. A. Shinder, C. Feliciani, G. M. Shivji, H. Suzuki, P. Amerio, P. Toto, and D. N. Sauder. 1999. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J. Immunol. 162:277.
46. Yokozeki, H., K. Takayama, O. Ohki, T. Satoh, T. Umeda, I. Katayama, and K. Nishioka. 1998. Comparative analysis of CD80 and CD86 on human Langerhans cells: expression and function. Arch. Dermatol. Res. 290:547.
47. Chatelain, R., A. Wollenberg, C. Martin, A. Panhans-Gross, T. Bieber, K. Degitz, and M. Heckmann. 1998. IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts. Arch. Dermatol. Res. 290:477.
48. Hosoi, J., H. Ozawa, and R. D. Granstein. 1999. β-Endorphin binding and regulation of cytokine expression in Langerhans cells. Ann. NY Acad. Sci. 885:405.
49. Lore, K., A. Sonnerborg, A. L. Spetz, U. Andersson, and J. Andersson. 1998. Erratum to "Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells." J. Immunol. Methods 218:173.
50. Chen, G., K. Kang, S. Kang, A. H. Rook, M. Kubin, J. J. Voorhees, and K. D. Cooper. 1996. Differential induction of IL-12 p40 and IL-10 mRNA in human Lnagerhans' cells and keratinocytes by in vivo occlusion, vehicle, and all-trans retinoic acid. J. Cutan. Med. Surg. 1:74.
51. Allescher, H. D., M. Kurjak, A. Huber, P. Trudrung, and V. Schusdziarra. 1996. Regulation of VIP release from rat enteric nerve terminals: evidence for a stimulatory effect of NO. Am. J. Physiol 271:G568.
52. Ganea, D., and M. Delgado. 2001. Neuropeptides as modulators of macrophage functions: regulation of cytokine production and antigen presentation by VIP and PACAP. Arch. Immunol. Ther. Exp. 49:101.
53. Martinez, C., M. Delgado, C. Abad, R. P. Gomariz, D. Ganea, and J. Leceta. 1999. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93:126.
54. Goetzl, E. J., J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar. 2001. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA 98:13854.
55. Voice, J. K., C. Grinninger, Y. Kong, Y. Bangale, S. Paul, and E. J. Goetzl. 2003. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170:308.
56. Delgado, M., J. Leceta, R. P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J. Immunol 163:3629.
57. Delgado, M., C. Abad, C. Martinez, J. Leceta, and R. P. Gomariz. 2001. Vasoactive intestinal peptide prevents experimental arthritis by down-regulating both autoimmune and inflammatory components of the disease. Nat. Med. 7:563.
58. Abad, C., C. Martinez, M. G. Juarranz, A. Arranz, J. Leceta, M. Delgado, and R. P. Gomariz. 2003. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124:961.